The Valley Desk

NCT06957080 · Interventional trial

A Study of 2 Doses of Remigromig (EYE103) Compared With Ranibizumab (0.5 mg) in Participants With DME

Overall registry status Active not recruiting

Phase 2 · Phase 3

Conditions Diabetic Macular Edema (DME)

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov